Navigation Links
Transdermal HRT not cardioprotective in postmenopausal women with CAD ,,

Transdermal hormone replacement therapy (HRT) does not reduce the risk of cardiac events in postmenopausal women with existing coronary artery disease (CAD). In the PHASE trial (Papworth HRT Atherosclerosis Study), researchers randomized 255 postmenopausal women with angiographically proven coronary artery disease to receive either transdermal HRT--17-beta-estradiol with or without cyclic norethisterone--or no hormone replacement therapy. The women were followed for 4 years. Overall, 134 women received hormone replacement therapy. Of these, 58 had a previous hysterectomy. The other 121 women served as controls.

On intention-to-treat analysis, there was no statistical difference in the incidence of unstable angina requiring hospitalization, MI or premature death from heart disease in women receiving HRT and women not receiving the therapy. Respectively, the average event rates were 15.6 and 12.6 per 100 patient-years. Results from the PHASE study also seem to indicate an increased risk of thromboembolic complications, such as stroke, with HRT. This observation is supported by results from the HERS study, a randomized trial carried out in the US that included 3000 women, and was designed to assess the cardioprotective effect of combined HRT in women with documented CAD. It may therefore be appropriate that women with proven coronary artery disease should not commence HRT. Nevertheless, women receiving HRT for more than 2 years should continue.

Page: 1

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
2. Transdermal Vaccine Effective in Treating Alzheimers Disease in Mice
3. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
4. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
5. Enlarged waistline may predict atherogenesis for postmenopausal women
6. Research explains why postmenopausal women accumulate abdominal fat.
7. Testosterone Therapy can improve sexual function in postmenopausal women
8. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
9. Starvation in pregnant women can cause heart disease to their children
10. Brisk Walking lowers memory loss in women
11. Young womens woes
Post Your Comments:

(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology: